Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
Pharmacology, Toxicology and Pharmaceutical Science
3
3%
Other
8
9%
Unknown
31
36%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2026.
All research outputs
#2,030,625
of 32,942,026 outputs
Outputs from BMJ Open
#3,426
of 29,154 outputs
Outputs of similar age
#41,265
of 512,144 outputs
Outputs of similar age from BMJ Open
#66
of 546 outputs
Altmetric has tracked 32,942,026 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 29,154 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.9. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 512,144 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 546 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.
